Clinical trials: Systemic Sclerosis Pulmonary
Pulmonary Arterial Hypertension, Systemic Sclerosis
A Clinical Trial of Ambrisentan and Tadalafil in Pulmonary Arterial Hypertension Associated With Systemic Sclerosis
This will be a 36-week, single group, open label study assessing the effects of Tadalafil plus Ambrisentan combination therapy in patients with pulmonary arterial hypertension associated with the scleroderma spectrum of disease…
- Conditions
- Pulmonary Arterial Hypertension, Systemic Sclerosis, Scleroderma Spectrum of Diseases, Connective Tissue Disease
- Trial name
- ATPAHSS (NCT01042158)
- Testing
- tadalafil and ambrisentan upfront combination therapy
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Johns Hopkins University
Systemic Sclerosis
Personalized Home Respiratory Rehabilitation Program for Subjects With Systemic Sclerosis With Early Lung Disease
Systematic sclerosis (SSc) is a potentially severe disease characterized by various visceral involvements including lung. The investigators hypothesize that a respiratory rehabilitation program specifically designed for people…
- Trial name
- SCLERESPIR (NCT05533034)
- Testing
- Rehabilitation
- Where
- France
- Volunteers
- 15 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Systemic Sclerosis, Pulmonary; Hypertension
Dimethyl Fumarate (DMF) in Systemic Sclerosis-Associated Pulmonary Arterial Hypertension
A double-blinded, placebo-controlled study of Dimethyl fumarate (DMF) in 34 Systemic Sclerosis-Pulmonary Hypertension (SSc-PAH) patients.
- Trial name
- NCT02981082
- Testing
- Dimethyl Fumarate (DMF)
- Where
- 4 sites in United States
- Volunteers
- 6 people
- Sponsor
- Robert Lafyatis
Scleroderma, Systemic, Lung Diseases, Interstitial
Functional Exercise Tests in Patients With Systemic Sclerosis
The aim of the study is to examine the validity of peripheral oxygen saturation measurement during the 6-minute walk test in patients with Systemic Sclerosis (SSc) and to examine the utility of two other functional tests as…
- Conditions
- Scleroderma, Systemic, Lung Diseases, Interstitial, Pulmonary Arterial Hypertension, Acroosteolysis
- Trial name
- NCT04650659
- Testing
- 6-minute walk test part one, 6-minute walk test part two, 1-minute sit-to-stand test
- Where
- Denmark
- Volunteers
- 83 people
- Sponsor
- University of Aarhus
Systemic Sclerosis
Nitric Oxide Lung Diffusing Capacity in Systemic Sclerosis
To date, two devices to measure nitric oxide lung diffusing capacity (DLNO) are commercially available in Europe. Previous research has shown systematic between-device differences in lung diffusing capacity outcomes in healthy…
- Trial name
- NCT05505617
- Testing
- Single-breath nitric oxide lung diffusing capacity measurements according to type of device in random order.
- Where
- Switzerland
- Volunteers
- 9 people
- Sponsor
- Holger Dressel
Autoimmune Disorders, Systemic Sclerosis
Phase I/II Study of AD-PluReceptor Plus Tafasitamab-cxix and Lymphodepleting Chemotherapy in Patients With Autoimmune Disorders
The goal of Safety Lead-In is to confirm the safety of tafasitamab when given to patients with SSc, SLE, and LN. The goal of Phase 1 is to find the recommended dose of AD-PluReceptor-NK cells in combination with tafasitamab and…
- Conditions
- Autoimmune Disorders, Systemic Sclerosis, Systemic Lupus Erythematosus, Lupus
- Trial name
- NCT06434363
- Testing
- Tafasitamab, Fludarabine phosphate, Cyclophosphamide
- Where
- 2 sites in United States
- Volunteers
- 47 people
- Sponsor
- M.D. Anderson Cancer Center
Interstitial Lung Disease, Systemic Sclerosis
The Role of Gastroesophageal Reflux in Scleroderma Pulmonary Fibrosis
Scarring of the lungs is common in patients with scleroderma and is one of the main causes of death. Patients with scleroderma very frequently have problems with their gullet (esophagus), the food pipe that leads into the…
- Conditions
- Interstitial Lung Disease, Systemic Sclerosis, Gastroesophageal Reflux
- Trial name
- NCT02136394
- Testing
- Gastro-esophageal reflux
- Where
- 2 sites in United Kingdom
- Volunteers
- 100 people
- Sponsor
- Royal Brompton & Harefield NHS Foundation Trust
Systemic Sclerosis, Pulmonary Hypertension
Evaluating Pulmonary Arterial Hypertension in Patients With Systemic Sclerosis
Doppler signals can be recorded from the lung parenchyma by means of a pulsed Doppler ultrasound system incorporating a special signal processing package- the Transthoracic Parametric Doppler (TPD) (Echosense Ltd., Haifa…
- Trial name
- NCT02339961
- Testing
- Ultrasound radiation
- Sponsor
- Echosense Ltd.
Pulmonary Hypertension
Endothelial Function in Patients With Scleroderma or Cirrhosis With and Without Pulmonary Hypertension
Pulmonary arterial hypertension (PAH) is a condition characterized by an increased pulmonary vascular resistance that can lead to right heart failure and death.
- Trial name
- NCT01729611
- Where
- United States
- Volunteers
- 119 people
- Sponsor
- The Cleveland Clinic
Pulmonary Hypertension, Systemic Sclerosis (SSc)
Multicenter Study on the Development of Pulmonary Arterial Hypertension Screening Models Based on Artificial Intelligence for Patients With Systemic Sclerosis
Pulmonary Arterial Hypertension (PAH) is a rare and severe condition that can be associated with Systemic Sclerosis (SSc), significantly worsening the prognosis of the latter disease.
- Conditions
- Pulmonary Hypertension, Systemic Sclerosis (SSc), Systemic Sclerosis-Associated PAH
- Trial name
- ARENAS (NCT07236970)
- Where
- 5 sites in Spain
- Volunteers
- 350 people
- Sponsor
- Alejandro Cruz Utrilla
Systemic Sclerosis, Interstitial Lung Disease
Evaluation of HRCT Patterns in Systemic Sclerosis-associated Interstitial Lung Disease
Systemic sclerosis (SSc) is a heterogeneous systemic autoimmune disease with distinct prognosis according to patients. Interstitial lung disease (ILD) concerns almost 50 % of SSc patients and represents the main cause of…
- Trial name
- LUNGSCLEROCT (NCT05482607)
- Where
- France
- Volunteers
- 100 people
- Sponsor
- Central Hospital, Nancy, France
Interstitial Lung Disease With Systemic Sclerosis
Evaluation of Efficacy and Safety of Rituximab and Mycophenolate Mofetil Combination in Patients With Interstitial Lung Disease Related to Systemic Sclerosis
The goal of this clinical trial is to evaluate the efficacy on lung function after 24 weeks of rituximab + MMF combination comparatively to placebo + MMF combination in patients with SSc-ILD severe at the initial assessment or at…
- Trial name
- EVER-ILD 3 (NCT06549231)
- Testing
- Rituximab
- Where
- France
- Volunteers
- 102 people
- Sponsor
- University Hospital, Tours
Scleroderma, Pulmonary Hypertension
Sleep Disturbances and Pulmonary Artery/Aorta Diameter in Scleroderma Patient
To determine sleep disturbance, pulmonary function test, 6 minute walk, echocardiogram abnormality, arterial blood gas, ventilation/perfusion scan of the chest in Scleroderma patient with Pulmonary Hypertension.
- Trial name
- Scleroderma (NCT00566137)
- Volunteers
- 50 people
- Sponsor
- Northwell Health
Scleroderma, Systemic
Pulmonary Involvement in Scleroderma: A Clinical Study of the Safety and Efficacy of Mycophenolate Mofetil in Scleroderma Patients With Lung Involvement
Researchers from the Division of Pulmonary and Critical Care Medicine at University of California, San Francisco (UCSF) are conducting a study to evaluate whether mycophenolate mofetil (an immunosuppressive medication, trade…
- Trial name
- NCT00333437
- Testing
- Mycophenolate mofetil
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- University of California, San Francisco
Chronic Inflammatory Disease, Angioedema
Deployment o the Multidisciplinary Prospective Cohort Imminent
Immune-mediated inflammatory diseases (IMIDs) most often affect young patients and have high impact on morbidity and mortality with a significant alteration in the quality of life of patients with professional, social and…
- Conditions
- Chronic Inflammatory Disease, Angioedema, Severe Asthma, Lupus
- Trial name
- IMMINeNT (NCT04334031)
- Testing
- Biobanking with genetic analysis, SF-12 questionnaire
- Where
- France
- Volunteers
- 2,200 people
- Sponsor
- University Hospital, Lille
Interstitial Lung Disease With Systemic Sclerosis
Pelvic Floor Dysfunction in Pulmonary Systemic Sclerosis
Systemic sclerosis (SSc) is a heterogeneous multisystem disease characterized by vascular dysfunction, immune abnormalities, and progressive fibrosis of the skin and internal organs.
- Trial name
- NCT07817160
- Testing
- Pelvic Floor Health Knowledge Assessment, Pelvic Floor Dysfunction Assessment, Core Endurance Assessment
- Where
- Turkey (Türkiye)
- Volunteers
- 37 people
- Sponsor
- Biruni University
Interstitial Lung Disease, Pulmonary Hypertension
Hyperpolarized Xenon MRI in Adults With Pulmonary Hypertension in Interstitial Lung Disease and Systemic Sclerosis
This study aims to evaluate a noninvasive magnetic resonance imaging technique using hyperpolarized xenon gas to measure lung function in adults with interstitial lung disease, pulmonary hypertension, and systemic sclerosis.
- Conditions
- Interstitial Lung Disease, Pulmonary Hypertension, Systemic Sclerosis
- Trial name
- NCT07821398
- Testing
- Hyperpolarized 129 Xenon Gas
- Volunteers
- 51 people, healthy volunteers welcome
- Sponsor
- Bastiaan Driehuys
Scleroderma, Systemic, Hypertension, Pulmonary
Stress Echocardiography in the Detection of Pulmonary Arterial Hypertension in Systemic Sclerosis Patients
The purpose of this study is to assess the value in terms of sensitivity, specificity and likelihood ratio of the stress echocardiography in the screening of pulmonary arterial hypertension in patients with systemic sclerosis and…
- Trial name
- NCT01202045
- Where
- Canada
- Sponsor
- Paul Farand
Pulmonary Arterial Hypertension, HIV Infection
Auto-immunity and Pulmonary Arterial Hypertension
The investigators have recently evidenced the presence of antibodies to endothelial cells and fibroblasts in patients with idiopathic or SSc-associated PAH.
- Conditions
- Pulmonary Arterial Hypertension, HIV Infection, Congenital Heart Defect, Systemic Sclerosis
- Trial name
- Auto-HTAP (NCT01208792)
- Testing
- skin biopsy, Blood Sample
- Where
- 3 sites in France
- Volunteers
- 629 people, healthy volunteers welcome
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Scleroderma, Pulmonary Hypertension
Endothelial Biomarkers of Systemic Sclerosis-associated Pulmonary Hypertension
Systemic sclerosis (SSc, AKA scleroderma) is an autoimmune condition characterized by endothelial damage and progressive fibrosis of the skin and internal organs.
- Trial name
- BOSS-PH (NCT03459716)
- Testing
- No intervention
- Where
- United States
- Volunteers
- 56 people
- Sponsor
- Louisiana State University Health Sciences Center in New Orleans